


Curriculum Vitae

**CV must be written in English*

Personal Information		
	Title (i.e. Prof., Dr., etc.)	Prof.
	Name (First / Middle / Last)	Edward V. Loftus, Jr.
	Degree (i.e. MD, MSc, PhD, etc.)	M.D.
	Country	United States of America
	Affiliation	Mayo Clinic College of Medicine and Science

Educational Background

1980.09 – 1984.05	B.S., Biology—Villanova University, Villanova, PA, USA
1984.09 – 1988.05	M.D., Medicine—University of Pennsylvania, Philadelphia, PA, USA
1988.06 -- 1991.06	Residency, Internal Medicine, Temple University Health Sciences Ctr, Philadelphia, PA, USA
1992.06 -- 1995.06	Fellowship, Gastroenterology, Mayo Graduate School of Medicine, Rochester, MN, USA

Professional Experience

1998.07 – present	Consultant, Division of Gastroenterology and Hepatology, Mayo Clinic
2023.01 -- present	Maxine and Jack Zarrow Family Professor of Gastroenterology, Mayo Clinic College of Medicine and Science

Professional Organizations

1992 - present	Member, American Gastroenterological Association
2012 -- 2016	Co-Chair and Chair, Immunology, Microbiology and Inflammatory Bowel Disease Section, AGA Institute Council
1992 – present	Member, American College of Gastroenterology
1992 – present	Member, American Society for Gastrointestinal Endoscopy
1994 – present	Member, Crohn's & Colitis Foundation
	Associate Editor, American Journal of Gastroenterology 2003-2009
	Associate Editor, Inflammatory Bowel Diseases, 2006-2012
	Associate Editor, Clinical Gastroenterology & Hepatology, 2022-2028

Main Scientific Publications

- (selected from >500 peer-reviewed articles)
-
- Loftus EV, Silverstein MD, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota, 1940-93: incidence, prevalence, and survival. *Gastroenterology* 1998;114:1161-1168.
- Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. *Gastroenterology* 1999;117:49-57.
- Loftus EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmsted County, Minnesota, 1940-93:

- incidence, prevalence, and survival. *Gut* 2000;46:336-43.
6. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. *Gastroenterology* 2001 Aug; 121(2):255-60. PMID:11487534.
 7. Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. *Gastroenterology* 2002 Apr; 122(4):875-80. PMID:11910338.
 8. Loftus EV, Crowson CS, Sandborn WJ, et al. Long-term fracture risk in patients with Crohn's disease: A population-based study in Olmsted County, Minnesota. *Gastroenterology* 2002 Aug; 123(2):468-75. PMID:12145800.
 9. Loftus EV Jr, Achenbach SJ, Sandborn WJ, et al. Risk of fracture in ulcerative colitis: a population-based study from Olmsted County, Minnesota. *Clin Gastroenterol Hepatol* 2003 Nov; 1(6):465-73. PMID:15017646.
 10. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. *Gastroenterology* 2004 May; 126(6):1504-17.
 11. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. *Gut* 2005 Jan; 54(1):91-6. PMID:15591511. PMCID:1774346. DOI:10.1136/gut.2004.046615.
 12. Solem CA, Loftus EV Jr, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. *Inflamm Bowel Dis* 2005;11(8):707-712. PMID: 16043984.
 13. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. *Gastroenterology* 2006 Apr; 130(4):1039-46. PMID:16618397.
 14. Jess T, Loftus EV Jr, Harmsen WS, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940-2004. *Gut* 2006 Sep; 55(9):1248-54. Epub 2006 Jan 19. PMID:16423890.
 15. Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. *Inflamm Bowel Dis* 2006 Dec; 12(12):1093-100. PMID:17119382.
 16. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. *Inflamm Bowel Dis* 2007 Mar; 13(3):254-61.
 17. Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. *Gastroenterology* 2008;134(4):929-936. PMID: 18294633.
 18. Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. *Am J Gastroenterol.* 2008 Dec; 103(12):3132-41. Epub 2008 Oct 03. PMID:18853973.
 19. *Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn's disease in population-based cohorts. *Am J Gastroenterol.* 2010 Feb; 105(2):289-97. Epub 2009 Oct 27. PMID:19861953.
 20. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort. *Gastroenterology* 2010; 139(4):1147-55. PMID:20637205.
 21. Fenta YA, Tello N, Jung JA, et al. Inflammatory bowel disease and asthma: a population-based, case-control study. *Inflamm Bowel Dis.* 2010 Nov; 16(11):1957-62. PMID:20848463.
 22. Peyrin-Biroulet L, Loftus EV Jr, Tremaine WJ, et al. Perianal Crohn's disease findings other than fistulas in a population-based cohort. *Inflamm Bowel Dis.* 2012 Jan; 18(1):43-8. Epub 2011 Feb 23. PMID:21351216.
 23. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). *Am J Gastroenterol.* 2012 Nov; 107 (11):1693-701. PMID:22945286.
 24. Shivashankar R, Loftus EV, Tremaine WJ, et al. Incidence of spondyloarthritis in patients with Crohn's disease: a population-based study. *J Rheumatol* 2012 Nov; 39(11):2148-52. PMID:22984277.
 25. Yun HD, Kroebe E, Fenta Y, et al. Asthma and pro-inflammatory conditions: a population-based retrospective matched cohort study. *Mayo Clinic Proc* 2012; 87(10):953-60. PMID:22980164.
 26. Holubar SD, Pendlimari R, Loftus EV Jr, et al. Drivers of cost after surgical and medical therapy for chronic ulcerative colitis: a nested case-cohort study in Olmsted County, Minnesota. *Dis Colon Rectum.* 2012 Dec; 55(12):1258-65. PMID:23135584.
 27. Figueroa JJ, Loftus EV Jr, Harmsen WS, et al. Peripheral neuropathy incidence in inflammatory bowel disease: A population-based study. *Neurology.* 2013 Apr 30; 80(18):1693-7. PMID:23576624.
 28. *Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. *Inflamm Bowel Dis.* 2013 Aug; 19(9):1858-66 PMID:23660997.
 29. *Shivashankar R, Loftus EV Jr, Tremaine WJ, et al. Incidence of spondyloarthritis in patients with ulcerative colitis: a population-based study. *J Rheumatol.* 2013 Jul; 40(7):1153-7. PMID:23678160.
 30. Feagan BG, Sandborn WJ, D'Haens G, et al. The role of centralized reading of endoscopy in a randomized

- controlled trial of mesalamine for ulcerative colitis. *Gastroenterology*. 2013 Jul; 145(1):149-157. e2. PMID: 23528626.
31. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2014 Feb; 12(2):210-218. PMID: 23644389.
 32. Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. *Gastroenterology* 2015 Jan 148(1):64-76. PMID: 25263803.
 33. Yadav S, Dave M, Edakkanambeth Varayil J, et al. A population-based study of incidence, risk factors, clinical spectrum, and outcomes of ischemic colitis. *Clin Gastroenterol Hepatol* 2015 Apr; 13(4):731-738. PMID: 2510936.
 34. Yadav S, Singh S, Harmsen WS, et al. Effect of medications on risk of cancer in patients with inflammatory bowel diseases: a population-based study from Olmsted County, Minnesota. *Mayo Clin Proc* 2015 Jun; 90(6):738-746.
 35. Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. *Clin Gastroenterol Hepatol* 2016 Jan; 14(1):65-70.
 36. Singh S, Heien HC, Sangaralingham LR, et al. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. *Aliment Pharmacol Ther* 2016 May; 43(9): 994-1003. PMID: 26991059.
 37. Singh S, Heien HC, Sangaralingham LR, et al. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naïve patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2016 Aug; 14(8):1120-1129. PMID: 27058635.
 38. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, et al. Cumulative length of bowel resection in a population-based cohort of patients with Crohn's disease. *Clin Gastroenterol Hepatol* 2016 Oct; 14(10):1439-44. PMID: 27155552.
 39. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2016 Nov; 375(20):1946-1960. PMID: 27959607.
 40. Loftus EV Jr, Colombel JF, Schreiber S, et al. Safety of long-term treatment with certolizumab pegol in patients with Crohn's disease, based on a pooled analysis of data from clinical trials. *Clin Gastroenterol Hepatol* 2016 Dec; 14(12): 1753-1762. PMID: 27464588.
 41. Loftus EV Jr, Colombel JF, Feagan B, et al. Long-term efficacy of vedolizumab for ulcerative colitis. *J Crohn's Colitis* 2017 Apr; 11(4): 400-411.
 42. Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. *Clin Gastroenterol Hepatol* 2017 Jun; 15(6): 857-863. PMID: 27856364.
 43. Aniwani S, Tremaine WJ, Raffals LE, et al. Antibiotic use and new-onset inflammatory bowel disease in Olmsted County, Minnesota, a population-based case-control study. *J Crohn's Colitis* 2018; 12(2):137-144. PMID: 29029150.
 44. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG Clinical Guidelines: Management of Crohn's Disease in Adults. *Am J Gastroenterol* 2018; 113(4):481-517. PMID: 29610508.
 45. Aniwani S, Harmsen WS, Tremaine WJ, et al. Overall and cause-specific mortality of inflammatory bowel disease in Olmsted County, Minnesota, from 1970 through 2016. *Mayo Clin Proc* 2018; 93(10):1415-1422. PMID: 30293558.
 46. Aniwani S, Pardi DS, Tremaine WJ, et al. Increased risk of acute myocardial infarction and heart failure in patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2018; 16(10):1607-1615. PMID: 29702298.
 47. Aniwani S, Harmsen WS, Tremaine WJ, et al. Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010. *Therap Adv Gastroenterol* 2019; 12:1756284819827692. PMID: 30792818.
 48. Park SH, Aniwani S, Harmsen WS, et al. Update on the natural course of fistulizing perianal Crohn's disease in a population-based cohort. *Inflamm Bowel Dis* 2019; 25(6):1054-60. PMID: 30346531.
 49. Panaccione R, Steinhart AH, Bressler B, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. *Clin Gastroenterol Hepatol* 2019; 17(9):1680-1713. PMID: 30853616.
 50. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. *N Engl J Med* 2019; 381(13):1215-1226. PMID: 31553834.
 51. Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease. *Gastroenterology* 2020; 158(8):2123-2138. PMID: 32044319.
 52. Loftus EV Jr, Feagan BG, Panaccione R, et al. Long-term safety of vedolizumab for inflammatory bowel disease. *Aliment Pharmacol Ther* 2020; 52(8):1353-1365. PMID: 32876349.
 53. Feagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis

- (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. *Lancet* 2021;397(10292):2372-2384. PMID: 34090625.
54. D'Haens GR, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. *Lancet* 2022;399(10340):2015-2030. PMID: 35644154.
 55. Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. *Lancet* 2022;399(10340):2031-2046. PMID: 35644155.
 56. Panes J, Colombel JF, D'Haens GR, et al. Higher vs standard adalimumab induction and maintenance dosing regimens for treatment of ulcerative colitis: SERENE UC trial results. *Gastroenterology* 2022;162(7):1891-1910. PMID: 35227777.
 57. D'Haens GR, Sandborn WJ, Loftus EV Jr, et al. Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results. *Gastroenterology* 2022;162(7):1876-1890. PMID: 35122766.
 58. Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. *Lancet* 2022;399(10341):2113-2128. PMID: 35644166.
 59. Sands BE, Irving PM, Hoops T, et al. Ustekinumab vs adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. *Lancet* 2022;399(10342):2200-2211. PMID: 35691323.
 60. Loftus EV Jr, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn's disease. *N Engl J Med* 2023;388(21):1966-1980. PMID: 37224198.
 61. Loftus EV Jr, Colombel JF, Takeuchi K, et al. Upadacitinib reduces ulcerative colitis symptoms as early as day 1 of induction treatment. *Clin Gastroenterol Hepatol* 2023;21(9):2347-2358. PMID: 36464141.
 62. Loftus EV Jr, Ananthakrishnan AN, Lee WJ, et al. Content validity and psychometric evaluation of the functional assessment of chronic illness therapy-fatigue (FACIT-Fatigue) in patients with Crohn's disease and ulcerative colitis. *Pharmacoecon Open* 2023;7(5):823-840. PMID:37296268.
 63. Louis E, Schreiber S, Panaccione R, et al, Loftus EV Jr, INSPIRE and COMMAND Study Group. Risankizumab for ulcerative colitis: two randomized clinical trials. *JAMA* 2024;332(11):881-897.
 64. Singh S, Loftus EV Jr, Limketkai BN, et al. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. *Gastroenterology* 2024;167(7):1307-1343.
 65. Battat R, Chang JT, Loftus EV Jr, Sands BE. IBD Matchmaking: Rational Combination Therapy. *Clin Gastroenterol Hepatol*. 2025 Feb; 23 (3):469-479 Epub 2024 July 25 PMID: 39025253 DOI: 10.1016/j.cgh.2024.05.051
 66. Loftus EV Jr, Torres J, Hou JK, Kahi CJ, Singh S. The Future of Inflammatory Bowel Disease Care. *Clin Gastroenterol Hepatol*. 2025 Feb; 23 (3):383-385 Epub 2024 Oct 24 PMID: 39454983 DOI: 10.1016/j.cgh.2024.10.004
 67. Hracs L#, Windsor JW#, Gorospe J, Cummings M, Coward S, Buie MJ, Quan J, Goddard Q, Caplan L, Markovinovic A, Williamson T, Abbey Y, Abdullah M, Abreu MT, Ahuja V, Raja Ali RA, Altuwaijri M, Balderramo D, Banerjee R, Benchimol EI, Bernstein CN, Brunet-Mas E, Burisch J, Chong VH, Dotan I, Dutta U, El Ouali S, Forbes A, Forss A, Geary R, Dao VH, Hartono JL, Hilmi I, Hodges P, Jones GR, Juliao-Banos F, Kaibullayeva J, Kelly P, Kobayashi T, Kotze PG, Lakatos PL, Lees CW, Limsrivilai J, Lo B, Loftus EV Jr, Ludvigsson JF, Mak JWY, Miao Y, Ng KK, Okabayashi S, Olen O, Panaccione R, Paudel MS, Quresma AB, Rubin DT, Simadibrata M, Sun Y, Suzuki H, Toro M, Turner D, Iade B, Wei SC, Yamamoto-Furusho JK, Yang SK, Ng SC, Kaplan GG, Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group. Global evolution of inflammatory bowel disease across epidemiologic stages. *Nature*. 2025 Jun; 642 (8067):458-466 Epub 2025 Apr 30 PMID: 40307548 PMCID: PMC12158780 DOI: 10.1038/s41586-025-08940-0
 68. Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, Ha CY. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol*. 2025 Jun 3; 120 (6):1225-1264 Epub 2025 June 03 PMID: 40701562 DOI: 10.14309/ajg.0000000000003465